Skip to main content

Moberg Pharma Annual Report for July 2019 – December 2020

Moberg Pharma´s Annual Report for July 2019 – December 2020 has been published and is available on

About this information
This information is information that Moberg Pharma AB (publ.) is obliged to make public in accordance with the Securities Market Act. The information was submitted for publication, through the contact persons set out below at 08.00 CET on April 19, 2021.

For additional information, please contact:
Anna Ljung, VD, phone: +46 707 66 6030, e-mail:
Mark Beveridge, CFO, phone: +46 76 805 82 88, e-mail:

About Moberg Pharma,
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company’s main asset, MOB-015, is a novel topical treatment for onychomycosis. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in Europe and Japan, among others, and the company's intention is to submit a registration application during the second half of 2021 in Europe. Moberg Pharma is headquartered in Stockholm and the company’s shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB).